Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays

about

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels

P2860

Q57816058-6B60456B-03B4-49E5-9DA4-70CB0916D7FE Q58701964-9CDEBF53-0324-4697-BA63-318867203EE6

P2860

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays

Item

http://www.wikidata.org/entity/Q41078498

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays

@en

type

Item

label

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays

@en

prefLabel

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays

@en

P1476

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays

@en

P2093

Fernando Magro

http://www.w3.org/2001/XMLSchema#string

Helena Tavares de Sousa

http://www.w3.org/2001/XMLSchema#string

Isadora Rosa

http://www.w3.org/2001/XMLSchema#string

Joana Afonso

http://www.w3.org/2001/XMLSchema#string

João Carvalho

http://www.w3.org/2001/XMLSchema#string

P2860

The Measurement of Observer Agreement for Categorical Data

Significance of low level infliximab in the absence of anti-infliximab antibodies.

Physicochemical characterization of Remsima.

Clinical pharmacokinetics and use of infliximab.

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.

Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives.

A review of CT-P13: an infliximab biosimilar.

P304

661-671

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756283X17722915

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Claudia Camila Dias

P577

2017-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28932268

http://www.w3.org/2001/XMLSchema#string

P932

5598811

http://www.w3.org/2001/XMLSchema#string

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays

about

P2860

P2860

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932